Clinical Trial

PRP for Glenohumeral Osteoarthritis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-12-28; most recent amendment 2025-10-01.
Status change: Not Yet Recruiting → Recruiting 2023-05-04
Trial Details
NCT Number NCT05675527
Lead Sponsor Hospital for Special Surgery, New York
Conditions Shoulder Osteoarthritis
Enrollment 135 participants
Start Date 2023-05-02
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-06